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Abstract
CXCL14, a relatively novel chemokine, is a non-ELR (glutamic acid-leucine-arginine) chemokine with a broad
spectrum of biological activities. CXCL14 mainly contributes to the regulation of immune cell migration, also
executes antimicrobial immunity. The identity of the receptor for CXCL14 still remains obscure and therefore the
intracellular signaling pathway is not entirely delineated. The present review summarizes the contribution of
CXCL14 in these two aspects and discusses the biological mechanisms regulating CXCL14 expression and potential
CXCL14 mediated functional implications in a variety of cells.
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Background
Chemokines are 8–14 kDa chemoattractant cytokines
mainly regulating cell migration that play an important
role in immune surveillance, inflammation, and cancer
[1–3]. Chemokines induce intracellular signaling
through G protein-coupled cell-surface receptors [3].
They contain several (usually four) conserved cysteine
residues. Based on the arrangement of these cysteine
residues, two major chemokine groups have been cate-
gorised- the CC family with the first two cysteines adja-
cent to each other, and the CXC family that has one
amino acid residue between the two cysteines. The che-
mokine (C-X-C Motif ) ligand 14 gene (also known as
BRAK, BMAC or Mip-2γ), located on human chromo-
some 5q31, is expressed as a 99 amino acid residue pre-
cursor protein, which is processed to a 77 amino acid
mature protein with a molecular weight of 9.4 kDa hav-
ing a highly basic isoelectric point of 9.9 (Fig. 1).
CXCL14 was initially identified from breast and kidney
cells in 1999 and is shown to be constitutively and
widely expressed in normal tissue, especially in the epi-
thelia [4, 5]. On the other hand, significant down-
regulation or complete loss of expression is observed in
many human cancer specimens and cancerous cell lines
[5–8]. The primary amino acid sequence of CXCL14 is
highly conserved in vertebrates [9]. Human and mouse
CXCL14 differ in only two amino acid residues. As a
non-ELR (Glu-Leu-Arg) CXC chemokine, CXCL14 has a
short NH2-terminal end with only two amino acids (Ser-
Lys) prior to the first typical Cysteine residue, while other
CXC chemokines such as CXCL11 and CXCL12 have five
or more residues in their NH2-terminal region (Fig. 1),
which are essential for interaction with their cognate re-
ceptors [10, 11]. Another unique characteristic of CXCL14
worth mentioning is that it has a five consecutive amino
acid insertion (41VSRYR45) not seen in other CXC chemo-
kines, which was reported to be essential for its degrad-
ation in cancer cells [12]. These characteristics separate
CXCL14 from other CXC chemokines, which could be
critical determinants governing its functions.
Cellular sources of CXCL14
CXCL14 is expressed by a variety of immune and non-
immune cells (Fig. 2) either constitutively or following
distinct stimulatory influence. Freshly isolated resting
human peripheral blood mononuclear cells do not ex-
hibit CXCL14 expression at transcript (mRNA) level [6].
However following stimulation with lipopolysaccharide
(LPS), CXCL14 mRNA is detected in monocytes and B
cells, but not T cells [6]. The CXCL14 mRNA is also de-
tected in THP-1 cell line and monocyte-derived dendritic
cells (DCs), but not Jurkat cells [8]. Monocyte-derived
immature dendritic cells (iDCs) secrete CXCL14 at low
concentrations under basal conditions, which could be re-
markably up-regulated by activin A [13]. Those leukocytes
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expressing CXCL14 all can be chemoattracted by CXCL14
indicating an immune surveillance role for CXCL14 [7, 8].
It is known that CXCL14 protein is highly expressed in
healthy human epidermis and scattered cells of the der-
mis, while markedly less expression levels are observed in
psoriatic and atopic dermatitis lesions [14]. Subsequently,
it has been demonstrated that normal skin keratinocytes,
dermal fibroblasts, dermal endothelial cells, and lamina
propria cells but not epithelial cells in normal intestinal
tissues are all sources of CXCL14, but not the immortal
cell lines [15, 16]. The cutaneous CXCL14 is involved in
the recruitment of CD14+ DC precursors and influences
their differentiation to Langerhans cells [16]. Those
CXCL14-producing fibroblasts are co-localized with mac-
rophages, which suggests a role for CXCL14 in macro-
phage development [15]. Another study showed CXCL14,
as a much highly expressed gene in taste buds of tongue
from human, and it could be secreted into the saliva
suggesting an immune surveillance function for this
protein in line with the presence of leukocytes in human
saliva [17, 18]. In addition, CXCL14 present on blood ves-
sels in dermal plexus may be associated with its antiangio-
genic effect in cancers [16, 19]. Therefore the chief
cellular sources of CXCL14 as present in circulating blood
cells, the skin barrier and saliva suggest its potential
involvement in first line of innate and later acquired
immune defence against pathogenic intrusions.
Regulation of CXCL14 expression at transcript and
protein levels
So far, the molecular mechanisms governing the expres-
sion of CXCL14 and CXCL14 mediated functions are not
clear. It has been shown that CXCL14 expression could be
inhibited by inflammatory stimuli such as TNF-α and LPS
in epithelial tissues [4, 14]. Cigarette smoke condensate
also could significantly suppress CXCL14 expression in
normal human bronchial epithelial cells derived from
healthy and non-smoking young male [20]. CXCL14 is
significantly upregulated in inflamed joints of collagen-
induced arthritis and its overexpression exacerbates arth-
ritis in a mouse model, which is in line with the studies
carried out in patients with rheumatoid arthritis [21, 22].
In another study, Padilla et al., revealed that CXCL14
mRNA is markedly upregulated in the left anterior de-
scending coronary artery (LAD) and descending thoracic
aorta of obese pig as a result of the high-fat diet feeding,
which suggests a possible role of CXCL14 in the progress
of atherosclerosis [23]. In cultured porcine endothelial
cells, this upregulation is not LPS or NF-κB dependent
[23]. Not only could the expression of CXCL14 transcript
Fig. 1 Structural similarities of CXCL11, CXCL12 and CXCL14. a CXCL11, CXCL12 and CXCL14 are all small chemokines with a similar molecular
structure. The three chemokines all share a C-terminal α-helix and comprise high pI values. Structures of the molecules were obtained by RCSB
protein data bank and pdb-files were displayed with Jmol: an open-source Java viewer for chemical structures in 3D. http://www.jmol.org/. b
CXCL11, CXCL12 and CXCL14 share high amino acid sequence conservation with 4 cysteines, 2 lysines and 1 proline residue being conserved
throughout all 3 chemokines (conserved amino acids shown by asterisk *). Alignment was performed using Clustal Omega multiple sequence
alignment tool. (References: [12, 65–67])
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but CXCL14 also undergo post-transcriptional and post-
translational regulations. For example as an anti-microbial
peptide (AMP), CXCL14 is completely degraded by the
cysteine proteinase SpeB from a strictly human pathogen
Streptococcus pyogenes [24].
Since a lot of research over years has been done to
study CXCL14 mediated effects in cancer, its expres-
sional regulation has been explored in several types of
carcinomas. RhoBTB2, an atypical member of the Rho
family, as a tumour suppressor which is downregulated
in a large proportion of breast and lung cancers [25], is
able to positively regulate CXCL14 expression in normal
and cancerous epithelial cells [26]. In breast cancer cells,
reactive oxygen species (ROS) caused by interrupted
mitochondrial respiratory chain increases CXCL14 ex-
pression through activation of the activator protein-1
(AP-1) [27]. As a consequence CXCL14 promotes cancer
cell motility through elevated cytosolic Ca2+ released from
the endoplasmic reticulum (ER) mediated through inter-
action between CXCL14 and inositol 1,4,5-trisphosphate
receptor on the ER [27]. Ultraviolet irradiation or serum
deprivation of oral squamous cell carcinoma cells in-
creases CXCL14 expression by stimulating the phosphor-
ylation of the mitogen-activated protein kinase (MAPK)
p38, which reduces cell viability [28]. In this study, the
suppression of ERK phosphorylation was also seen, in line
with the previous report of MEK-ERK induced downregu-
lation of CXCL14 by activation of epidermal growth factor
receptor (EGFR) in oral carcinoma cells [29, 30]. It is also
known that the phosphorylation of p38MAPK leads to ac-
tivation of AP-1 [31], which was shown to be essential for
elevation of CXCL14 expression as stimulated by ROS in
breast cancer cells. These data suggest p38MAPK may
play an important role through which different stress sig-
nal pathways regulate CXCL14 expression.
Due to its ill-defined receptor, intracellular signaling
cascade initiated by CXCL14 still remains largely illusive.
However it is known that CXCL14 can regulate calcium
influx, NF-κB activity, activation of AP-1, and NOS1 as





























Fig. 2 Schematic diagram showing the cellular sources of CXCL14, cells that have been demonstrated to express or release CXCL14 constitutively
of following inflammatory cues; the target cells on which CXCL14 exerts its chemotactic activity, modulates differentiation or executes microbicidal
actions thereby contributing to immune surveillance and immune defence
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translational mechanism for the loss of CXCL14 protein
is reported in cancer and immortalized cell lines, but
not in normal epithelial cells, which is regulated through
ubiquitin-mediated, the 26 S proteasome participated
degradation [12]. In human lung cancer cell line NCI-
H460, which does not express potential target GPCRs
for CXCL14, CXCL14 stimulates NF-κB activity to pro-
mote its proliferation and migration by binding to some
glycoproteins on cell surface [32]. In gastric adenocar-
cinoma tissues, the unusually high methylation in
CXCL14 promoter region contributes to the low expres-
sion levels of CXCL14 resulting in poor prognosis [33].
In prostate and breast cancer, it is reported that the
tumor-supportive effect of fibroblast-derived CXCL14
depends on nitric oxide synthase NOS1 mediated signal-
ing mechanisms [34, 35]. CXCL14 also facilitates inva-
siveness of pancreatic cancer cells by increasing nuclear
NF-κB p65 levels [36]. In head and neck squamous cell
carcinoma (HNSCC), CXCL14 expression and secretion
and its anti-tumor effect is negatively regulated by
RhoA/ROCK pathway. Therefore Fasudil, ROCK-specific
inhibitor can stimulate CXCL14 expression [37]. In clear
cell renal cell carcinoma, S100A6 (Calcyclin), as an
oncogenic protein, negatively regulates CXCL14 expres-
sion, and knockdown of S100A6 promotes CXCL14-
mediated apoptosis and promotes tumour progression
[38]. In osteosarcoma, activation of Iroquois homeobox
1 (IRX1), as a prometastatic protein, directly increases
CXCL14 expression, and promotes osteosarcoma meta-
static activity via elevated CXCL14/NF-κB signaling [39].
These experimental evidences from cancer research
could facilitate to build a research base for endeavours
in infection and inflammation or immunological re-
search to decipher the potential mechanisms by which
expression and stability of CXCL14 could be modulated.
Role of CXCL14 in mediating leukocyte migration
and differentiation
As mentioned before, ambiguities still surround the
identity of the cognate receptor for CXCL14. This makes
it difficult to investigate the downstream intracellular
signaling cascade of this chemokine completely. Re-
cently, it has been demonstrated that CXCL14 specific-
ally binds to CXCR4 with high affinity and supresses
CXCL12-induced migration of THP-1 and human CD34
+ bone marrow cells [40–42]. Another report indicates
that CXCL14 in the conditioned medium from CD31−
side population (SP) cells promotes cell migration
through CXCR4 on the migrated cells of the regenerated
pulp tissue in an ectopic tooth transplantation model.
Interestingly, CD31− SP cells express CXCL12 only to a
minimum extent [43, 44]. Thus conflicting experimental
observations from different working groups have led to
discrepancies regarding the chemotactic potential of
CXCL14, which are summarized in Table 1. Unlike some
other non-ELR CXC chemokines that are chemotactic
for activated T cells [45, 46], CXCL14 fails to promote
chemotaxis of naive or activated T cells [7, 8, 15].
Among other cells which have been indicated to display
chemotaxis towards CXCL14 are CESS (human B-cell
line), THP-1 (human monocyte leukemia cell line), hu-
man neutrophils, human and murine immature dendritic
cells, human monocytes (especially prostaglandin E2
(PGE2) or forsklin-treated monocytes), activated human
natural killer cells (NKs), and human uterine NKs [7, 8,
15, 45, 47]. Discrepancies might have risen due to differ-
ence in the methods of leukocyte isolation and use of
CXCL14 protein from different sources by researchers,
which include synthesised protein, murine CXCL14,
CXCL14 present in conditioned media from transfected
mammalian cell, and commercially available recombin-
ant proteins from different sources [6–8, 16]. Since the
availability of recombinant human CXCL14 (rCXCL14),
it has been demonstrated that CXCL14 effectively pro-
motes chemotaxis of only immature, but not mature
DCs both in vivo and in vitro [19, 48]. In tumour tissues,
the loss of CXCL14 is associated with reduced infiltra-
tion of DCs, which could otherwise elicit a specific anti-
tumor immunity [48]. CXCL14 can further promote DC
activation accompanied by up-regulation of NF-κB activ-
ity [48]. Moreover, Schaerli et al.,. demonstrated a role
of CXCL14 and the epidermal environment in selectively
recruiting blood CD14+ DC precursors to be differenti-
ated into epidermal Langerhans cells under steady-state
condition by using a human epidermal tissue model,
which is consistent with the constitutive expression of
CXCL14 in the epidermis of healthy skin [15, 16]. How-
ever, a series of synthetic CXCL14 variants with amino-
terminal extensions show no chemoattractant effect on
CD14high monocytes [16]. Presumably, the amino
terminus of CXCL14 might be important for its inter-
action with the chemotactic receptor on target cells
which respond to CXCL14. However, no significant dif-
ference is observed in the numbers of monocytes, mac-
rophages and DCs in blood, bone marrow, and
secondary lymphoid organs among CXCL14 knockout
mice and their wild type counterparts, or among the
CXCL14-transgenic (Tg) mice [22, 49]. Interestingly, en-
hanced T cell activation and proliferation was shown in
CXCL14-Tg mice compared to the control mice, despite
no alteration in the number of lymphocytes [22]. Very
recently, significantly reduced number of uterine NK
cells was demonstrated in CXCL14−/− pregnant uterus
as compared to CXCL14+/− pregnant uterus, which is in
line with the chemoattractive effect of CXCL14 on hu-
man uterine NK cells as observed in vitro [45, 50]. These
observations indicate that CXCL14 is not indispensable
for maintaining chemotaxis or steady state kinetics and
Lu et al. Journal of Inflammation  (2016) 13:1 Page 4 of 8
Table 1 Cellular sources, target cells and potential functional significance of CXCL14 to immune functions
Cells or tissues expressing CXCL14
as mRNA or protein
Target cells for CXCL14 Functional effects of CXCL14 Sources of recombinant
CXCL14 protein
Reference
mRNA detected in human heart,
brain, placenta, lung, liver, skeletal
muscle, kidney, and pancreas; colon
adenocarcinoma cell SW 485, and
melanoma cell MDA-MB-435
No in vitro effect on human
endothelial cell proliferation or
tubule formation; No chemotactic
effects on human or murine T cells,
B cells, monocytes, NK cells, or
granulocytes
Synthesized human CXCL14 1999 Hromas
et al. [5]
mRNA detected in mouse brain,
ovary, lung, and muscle; Human
intestine, colon, kidney, liver, spleen,
thymus, placenta, brain, pancreas,
skeletal muscle, heart, cervix, uterus,
and breast
B cells, macrophages, CESS
(human B cell line), A20
(murine B cell line), THP-1
(human monocyte
leukemia cell)
Chemoattraction of CESS and THP-1
cells; Inflammation induction in vivo
in Nude mice
Synthesized murine CXCL14 2000 Sleeman
et al. [7]
mRNA detected in human kidney,
intestine, brain, placenta, skeletal
muscle, liver, spleen, thymus, and
pancreas; very faint expression in
testis, ovary, heart, and lung.
Human neutrophils and
monocyte-derived DC
A strong chemoattractant for







Epithelium of tubules of mouse
kidney; hepatocytes in mouse liver;
monocyte-derived dendritic cell
(DC); THP-1
mRNA in human skin, kidney,
intestine, spleen, colon, muscle,
liver, brain, placenta, thymus, breast,
exocervix, ovary and heart;
squamous epithelium; oral epithelial
cells, epidermal keratinocytes; LPS
activated B cells and monocytes;
inflammatory and stromal cells
adjacent to carcinomas




mRNA in human epithelial layer of
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(PGE2) or forskolin (strong)
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development; CXCL14 signals
through Bordetella pertussis toxin-
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al. [15]
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turnover of immune cells in vivo and might have other
chemokines complementing its functions. Among all 48
human chemokines, only CXCL12 (also known as SDF-1α)
matches the high degree of CXCL14 conservation in verte-
brate species [51]. Both are known as evolutionary ancient
chemokines due to their highly conservative sequence
throughout different vertebrate classes and their homeo-
static roles, which suggests that CXCL14, evolved with
CXCL12, might have the potential to regulate the function
of the CXCL12-CXCR4 signaling axis or play a com-
pensatory role when CXCL12 is absent [9, 40, 43, 52, 53].
However, other report demonstrates that CXCR4 alone is
not sufficient to initiate CXCL14-mediated chemotactic
response. CXCL14 also fails to influence the CXCL12-
CXCR4 mediated signaling axis in Jurkat cells and
HEK293 cells transfected with CXCR4 [54]. So other
potential GPCR or signaling mediators still need to
be identified for CXCL14-specific biological activities
in co-operation with CXCR4.
Antimicrobial activity of CXCL14
Although human skin is constantly exposed to a variety
of microorganisms, normally no signs of infection or ex-
cessive microbial growth are shown on our healthy body
surfaces [55]. Apart from the physical barrier, the exist-
ence of abundant antimicrobial peptides (AMPs) con-
tributes to prevent a wide spectrum of bacteria, yeast,
and some enveloped viruses from infiltrating into the
live part of the epidermis [56–59]. Defensins and catheli-
cidin LL-37 are the main AMPs expressed in human
skin [58, 59]. Interestingly, CXCL14 shares striking com-
mon structural characteristics with them, including
large, positively charged patches on its molecular sur-
face, three anti-parallel β-strands shown in β-defensin,
and a C-terminal α-helix that is typical for cathelicidin
LL-37 (Fig. 1) [60]. CXCL14 and human β-defensin both
show bactericidal activity against Gram-positive coccoid
Finegoldia magna residing in skin epidermis and the
virulent pathogen Streptococcus pyogenes at similar con-
centrations [4]. Thus, in addition to its chemoattractant
effects on immune and inflammatory cells, recombinant
CXCL14 demonstrates direct antimicrobial effects
against Escherichia coli and Staphylococcus aureus, but
not Candida albicans at 10μg/ml [61]. Characteristic
topological formation of a large positive electrostatic
patch on the molecular surface of CXCL14 is required
for its antimicrobial activity as deciphered in comparison
of antimicrobial chemokines with non-antimicrobial
chemokines. Subsequently, CXCL14 has demonstrated
to have a broad range of antimicrobial effects against cu-
taneous Gram-positive bacteria and Candida albicans as
well as the Gram-negative enterobacterium Escherichia
coli, which could not be counteracted by increased salt
concentrations and skin-typical pH conditions [14].
Those antimicrobial activities exhibited by both human
and murine CXCL14 could be neutralized by anti-
CXCL14 mAb [14]. Since CXCL14 is constantly pro-
duced in the epidermis and dermis of healthy human
skin and other epithelial tissues but is markedly de-
creased in the presence of inflammation and disease,
it has been proposed that CXCL14 plays a unique
role in antimicrobial immunity prior to the establish-
ment of inflammation [4, 14, 15].
Moreover, CXCL14 also plays prominent anti-microbial
role in animal models of respiratory tract infection. It exe-
cutes bactericidal actions against Pseudomonas aerugi-
nosa, Streptococcus mitis, and Streptococcus pneumoniae
partially via bacterial membrane depolarization, damage
and via its binding affinity for bacterial DNA [62]. In this
study, the authors showed that the disulphide bonds and
the C-terminal α-helix of CXCL14 do not seem to be
responsible for its antimicrobial activity [62], although a
high proportion of cationic amino acids in the α-helix part
might be involved in the disruption of bacterial mem-
branes by binding with negatively charged molecules in
bacterial membranes. The N-terminal region of CXCL14
is critical for its antimicrobial activity, at least, against
Gram-negative bacteria such as E. coli and Pseudomonas
aeruginosa, while the CXCL14 fragment showed no
chemoattractant effect for human blood monocytes at
micromolar concentrations [62]. To substantiate the anti-
bacterial effects of CXCL14 both CXCL14 mRNA and
protein expression levels are shown to be increased
following Pseudomonas aeruginosa infection in the
lung tissue of wild type mice. On the other hand,
CXCL14-deficient mice exhibit reduced bacterial
clearance in the lungs infected with Streptococcus
pneumoniae but not Pseudomonas aeruginosa [62].
This is the first in vivo demonstration that CXCL14
has a role in host defence against lung infections
Table 1 Cellular sources, target cells and potential functional significance of CXCL14 to immune functions (Continued)
Human THP-1 cells and
iDCs











Induction of THP-1 migration;
antimicrobial activity to facilitate
bacterial clearance in mouse lung
Recombinant human
CXCL14
2015 Dai et al.
[62]
Lu et al. Journal of Inflammation  (2016) 13:1 Page 6 of 8
induced by Gram-positive bacteria. The exact anti-
microbial mechanism for CXCL14 remains to be deci-
phered. Nevertheless, it might be considered that
classical AMPs like defensins and cathelicidin exert
less influence on Gram-positive bacteria compared
with Gram-negative bacteria. For instance, cathelicidin
deficient mice showed an impaired lung bacterial
clearance in response to Gram-negative Pseudomonas
aeruginosa [63]. These studies suggest the possibility
that different structural properties of CXCL14 and
antimicrobial mode of action might be associated with
extermination of Gram-negative and Gram-positive
bacterial species. The molecular regions of CXCL14
acting as an AMP and a chemoattractant appears to
be different, and CXCL14 shows a non-redundant
role as an AMP in lung infections. Future studies util-
izing animal models of systemic infection like sepsis could
reveal the antimicrobial potential of CXCL14 not only as a
therapeutic alternative administered to these models but
decipher the role of active immune cell derived CXCL14
in providing antimicrobial defence under physiological
conditions.
Conclusions
During recent years of endeavours in the ever expanding
field of chemokine research CXCL14 has emerged as a
potential mediator of inflammatory processes and im-
mune response as highlighted in this review. It also
bears the potential to influence other chemokine func-
tions particularly that of CXCL12. Identification of its
cognate receptor in the coming years would help reveal
the molecular mechanisms by which CXCL14 might
influence immune response also uncover more cellular
targets under diverse pathophysiological conditions which
involve immune cells.
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